Cellectar Biosciences Inc (CLRB)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.37+0.85%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CLRB
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Expenses & Income | ||||||||||||||||
| R&D Expenses | 13.2 | 11.5 | 26.1 | 27.3 | 18.3 | 17.6 | 10.1 | 9.0 | 6.8 | 9.5 | 4.8 | 5.2 | 6.0 | 6.9 | 5.1 | 3.6 |
| Operating Income | (23.5) | (23.0) | (51.8) | (39.0) | (28.8) | (24.1) | (15.3) | (14.2) | (13.3) | (13.6) | (9.4) | (8.8) | (9.9) | (12.4) | (8.8) | (7.0) |
| Earnings from Continuing Operations | ||||||||||||||||
| Other Non-Operating Income / Expenses | 1.2 | 1.2 | 7.3 | (3.9) | (3.0) | 0.0 | 0.2 | 0.1 | 0.1 | 0.0 | 3.3 | 3.3 | 1.8 | 1.6 | (0.0) | (0.4) |
| Asset Writedown | — | — | — | — | — | — | — | — | 1.7 | — | — | — | — | — | — | — |
| EBT, Incl. Unusual Items | — | (21.8) | (44.5) | (42.8) | (31.9) | (24.1) | — | — | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | 0.1 | (0.1) | (0.1) | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Net Income | ||||||||||||||||
| Net Income | (22.3) | (21.8) | (44.6) | (38.0) | (31.8) | (24.1) | (15.1) | (14.1) | (13.2) | (13.6) | (6.2) | (5.5) | (8.1) | (10.8) | (8.8) | (7.4) |
| Per Share | ||||||||||||||||
| Basic EPS | (1.83) | (8.35) | (1.22) | (3.50) | (4.51) | (4.35) | (0.76) | — | — | — | — | — | — | — | — | — |
| Diluted EPS | (1.83) | (8.35) | (1.40) | (3.50) | (4.51) | (4.35) | (1.84) | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 12.2 | 2.6 | 36.6 | 12.2 | 7.1 | 5.6 | 19.8 | — | — | — | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | 12.2 | 2.6 | 37.1 | 12.2 | 7.1 | 5.6 | 19.8 | — | — | — | — | — | — | — | — | — |
| Supplemental | ||||||||||||||||
| EBITDA | — | (22.8) | (51.5) | (38.8) | (28.7) | (24.0) | (15.1) | (14.0) | (13.2) | (12.1) | (9.1) | (8.4) | (9.5) | (12.0) | (8.3) | (6.5) |
| EBIT | (23.5) | (23.0) | (51.8) | (39.0) | (28.8) | (24.1) | (15.3) | (14.2) | (13.3) | (13.6) | (9.4) | (8.8) | (9.9) | (12.4) | (8.8) | (7.0) |
| Effective Tax Rate | — | — | — | 0.1% | 0.2% | — | — | — | — | — | — | — | — | — | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.